Gossamer Bio (NASDAQ:GOSS) Posts Earnings Results, Misses Expectations By $3.57 EPS

Gossamer Bio (NASDAQ:GOSS) released its quarterly earnings data on Tuesday. The company reported ($7.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.79) by ($3.57), FiscalAI reports. The firm had revenue of $38.43 million during the quarter, compared to the consensus estimate of $12.16 million.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $11.28 on Wednesday. The stock’s fifty day moving average price is $10.71 and its two-hundred day moving average price is $35.96. Gossamer Bio has a one year low of $8.29 and a one year high of $309.60. The firm has a market cap of $68.92 million, a price-to-earnings ratio of -0.20 and a beta of 2.28.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Chardan Capital reaffirmed a “buy” rating on shares of Gossamer Bio in a research report on Monday, October 26th. Weiss Ratings lowered shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $256.00.

Gossamer Bio Company Profile

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.